BioTwin Announces a New Member to its Advisory Board - BioTwin | BioTwin

BioTwin Announces a New Member to its Advisory Board

Press Release | 08/24/2021

Quebec City, August 24th, 2021 – BioTwin is proud to introduce Neil D’Cruz to its advisory board. As a new member, Mr. D’Cruz will bring additional perspectives to help BioTwin broaden and validate its various business endeavours.

Neil D’Cruz was introduced to BioTwin by MaRS Growth Services, an Innovation Hub for high potential start-ups. MaRS Growth Services provides a network of experts in various fields including digital health, venture capital and talent recruitment. BioTwin’s Advisory Board is comprised of nine industry experts, including new member Neil D’Cruz. The company’s mission is to surround itself with individuals who possess experience in various fields to facilitate growth. The company is proud to be receiving expert guidance on its pursuit of innovation in artificial intelligence in preventive healthcare.

Members of the Advisory Board include:

Neil D’Cruz, advisor – business (new member)

An accomplished healthcare executive with 20+ years of Canadian, US and international healthcare and management consulting experience. Neil is a Management Consultant where he focuses on designing and implementing commercial growth and operational excellence plans for clients in Life Sciences and Healthcare. Previously, he was Vice President, Business Development, Innovation and Client Solutions at Dynacare where he led the business transformation and repositioning of the company, while establishing and building two businesses, Dynacare Insurance Solutions, a national leader, and Dynacare Plus, one of Canada’s largest for pay consumer digital health platforms.

Andy Sheldon, advisor – business

Chairman of the Board of IMV, he has over thirty years of experience in the pharmaceutical industry. He stands out for his participation in the creation of a therapeutic vaccine against bladder cancer.

Henry Saumier, advisor – business

Professional in the pharmaceutical industry in Canada, he is proficient in strategic planning, business development, international marketing, and management of executive teams.

Keven O’Brien, advisor – business & finances

President of WW Canada, he will bring exceptional management and strategic consulting experience.

Benoit Cyr, advisor – business

Executive Chairman of Feldan, and an angel investor with Anges Québec among others, he is a researcher as well as an investor specializing in start-up companies in the biotechnology sector.

Henrick Simard, advisor – business law

Partner in the Corporate and Commercial Law group of Fasken, he has expertise enabling him to support companies in their growth.

Claude Doré, advisor – finances

With over 20 years of experience in the financial field, he has in-depth knowledge of the challenges that high-growth technology companies can face.

Dr. Julien Martel, advisor – healthcare & business

Emergency Doctor in Montreal CHUM, he brings together technical and clinical knowledge, which leads him to an interest in artificial intelligence.

Dr. Yves Fradet, advisor – healthcare & business

A urologist specializing in oncology-urology and tumour immunology, he founded the Uro-Oncology Laboratory at the Cancer Research Center of Université Laval.


“The uniqueness of BioTwin’s offer will undoubtedly shake up the health sector in the foreseeable future. This is a company with great potential, and I am excited to play a role in helping the organization position itself on the global market.”

Neil D’CRUZ, Business Advisor at BioTwin

“BioTwin is privileged that Mr. D’Cruz has joined the existing advisors to help the company through its future growth phases, especially as he fully understands the company’s business opportunity. His unique expertise will allow a fresh perspective on BioTwin and its business model, enabling the organization to initiate its next projects and financial rounds.”

Louis-Philippe NOEL, General Manager and Co-Founder at BioTwin

About BioTwin

BioTwin harnesses AI, biomarkers, and biometrics to create a virtual human copy. These digital twins allow early detection and prediction of diseases and innumerable simulations. This technology will revolutionize the fields of wellness and healthcare by making personalized medicine a reality.



For more information

Share this
Share this